Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of ValiRx.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
ValiRx
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
180-186 Kings Cross Road London, WC1X 9DE
Telephone
Telephone
+44 (0)207 0732628
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

ValiRx had entered into an agreement with Kalos Therapeutics, whereby ValiRx would perform a range of preclinical evaluation experiments to determine whether to enter a full licensing agreement for KTH222.


Lead Product(s): KTH222

Therapeutic Area: Oncology Product Name: KTH222

Highest Development Status: PreclinicalProduct Type: Peptide

Recipient: Kalos Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ValiRx will benefit from Physiomics' expertise in modelling the effects of prostate cancer care, as well as the latest version of its Virtual TumourTM technology, which will be used to extract useful information from the additional data provided by the VAL201 clinical trial.


Lead Product(s): VAL201

Therapeutic Area: Oncology Product Name: VAL201

Highest Development Status: Phase I/ Phase IIProduct Type: Peptide

Recipient: Physiomics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel.


Lead Product(s): KTH222

Therapeutic Area: Oncology Product Name: KTH222

Highest Development Status: PreclinicalProduct Type: Peptide

Recipient: Kalos Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Agreement signed with the company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis.


Lead Product(s): VAL301

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY